Captrust Financial Advisors Sells 3,094 Shares of Organon & Co. (NYSE:OGN)

Captrust Financial Advisors lowered its position in shares of Organon & Co. (NYSE:OGN) by 11.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 24,364 shares of the company’s stock after selling 3,094 shares during the period. Captrust Financial Advisors’ holdings in Organon & Co. were worth $466,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Mercer Global Advisors Inc. ADV increased its position in Organon & Co. by 1.8% during the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 31,086 shares of the company’s stock valued at $674,000 after purchasing an additional 546 shares during the period. Ballentine Partners LLC increased its holdings in Organon & Co. by 3.0% during the second quarter. Ballentine Partners LLC now owns 19,105 shares of the company’s stock valued at $395,000 after buying an additional 552 shares during the period. Sippican Capital Advisors raised its stake in Organon & Co. by 4.3% in the third quarter. Sippican Capital Advisors now owns 15,230 shares of the company’s stock worth $291,000 after buying an additional 627 shares in the last quarter. Commerce Bank lifted its holdings in Organon & Co. by 5.5% during the third quarter. Commerce Bank now owns 12,168 shares of the company’s stock worth $233,000 after buying an additional 637 shares during the period. Finally, Signaturefd LLC lifted its holdings in Organon & Co. by 6.6% during the second quarter. Signaturefd LLC now owns 11,308 shares of the company’s stock worth $234,000 after buying an additional 698 shares during the period. 77.43% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

OGN has been the subject of several recent research reports. Evercore ISI raised Organon & Co. to a “strong-buy” rating in a research report on Wednesday, September 18th. JPMorgan Chase & Co. downgraded shares of Organon & Co. from a “neutral” rating to an “underweight” rating and boosted their target price for the stock from $18.00 to $20.00 in a report on Friday, September 6th.

Organon & Co. Price Performance

NYSE OGN opened at $15.37 on Friday. The firm’s fifty day simple moving average is $16.52 and its two-hundred day simple moving average is $19.23. The firm has a market capitalization of $3.96 billion, a P/E ratio of 3.05, a P/E/G ratio of 0.71 and a beta of 0.75. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73. Organon & Co. has a 12-month low of $11.31 and a 12-month high of $23.10.

Organon & Co. (NYSE:OGN) last announced its earnings results on Thursday, October 31st. The company reported $0.87 earnings per share for the quarter, missing the consensus estimate of $0.90 by ($0.03). Organon & Co. had a return on equity of 644.70% and a net margin of 20.30%. The business had revenue of $1.58 billion for the quarter, compared to analysts’ expectations of $1.56 billion. During the same quarter last year, the firm earned $0.78 earnings per share. The firm’s quarterly revenue was up 4.1% compared to the same quarter last year. Analysts forecast that Organon & Co. will post 3.89 EPS for the current fiscal year.

Organon & Co. Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, December 12th. Shareholders of record on Tuesday, November 12th were given a dividend of $0.28 per share. This represents a $1.12 annualized dividend and a yield of 7.29%. The ex-dividend date was Tuesday, November 12th. Organon & Co.’s dividend payout ratio is presently 22.22%.

About Organon & Co.

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.